Phase 2 Study of Eculizumab (Soliris) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting
Study in 14 Patients Shows Clinically Meaningful Trend inDisease Severity ScoreEculizumab Achieves Strong Disease Improvement Signal andImportant Secondary Endpoints CHESHIRE, Conn.–(BUSINESS WIRE)–Sep 14, 2011 – AlexionPharmaceuticals,…
September 14th, 2011
Posted in
Drug